Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Gruppo Oncologico del Nord-Ovest
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05845450CT.gov Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | — | Recruiting | — | — | — |
NCT04705818CT.gov Combining Epigenetic And Immune Therapy to Beat Cancer. | — | Completed | — | — | — |
NCT04108481CT.gov Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT03206073CT.gov A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer | — | Completed | — | — | — |
NCT02888743CT.gov Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT02983578CT.gov Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT02669914CT.gov MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | — | Terminated | — | — | — |
NCT02811497CT.gov Study of Azacitidine and Durvalumab in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02740985CT.gov A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Durvalumab (this asset) | Gruppo Oncologico del Nord-Ovest | P2 | BB · 64 |
| Tipiracil | Mayo Clinic | P2 | BBB |
| Fluorouracilum | City of Hope Medical Center | P4 | BB |
| Oxaliplatin | First Affiliated Hospital of Zhejiang University | P4 | BB |
| Muamycin | City of Hope Medical Center | P3 | BB |
| Capecitabine | First Affiliated Hospital of Zhejiang University | P4 | BB |
| Pentoxifylline | Tanta University | P4 | BB |
| Irinotecan | City of Hope Medical Center | P3 | BB |
| Cyclophosphamide | City of Hope Medical Center | P3 | BB |
+42 more in the Colorectal Carcinoma cohort
Other indications for Durvalumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 70 |
| Primary Peritoneal Carcinoma | — | P2 | BB · 70 |
| Urothelial Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Durvalumab in Colorectal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/durvalumab-colorectal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →